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and warfarin do not differ significantly in real-world rates of composite stroke 
and systemic embolism and major, intracranial, or GI bleeding. Rivaroxaban was 
associated with significantly fewer VTE events and better treatment persistence 
compared with warfarin.
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Risk Of New ONset Diabetes with ROsuVastatiN theRaPy aND Quality 
Of life
Siwak A, Khan A., Gut M., Rasty S., Sakharkar P.
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Objectives: Statins have been shown to significantly reduce the cardiovascular 
risk. In recent studies, high potency statins have been associated with elevated fast-
ing plasma glucose (FPG) and glycated hemoglobin A1c (HbA1c) level. Rosuvastatin is 
widely prescribed statin medication for treating dyslipidemia. A systematic review 
was conducted to examine rosuvastatin’s effect on glycemia levels and quality of 
life. MethOds: Double-blind, randomized, clinical trials reporting changes in FBG, 
HbA1C, incidence of new onset diabetes and quality-adjusted life years (QALYs) 
with rosuvastatin therapy were included in this systematic review. Studies that 
were open label, non-randomized, observational, with combination therapies; case 
reports, less than four weeks duration and published in other than English language 
were excluded. Search was performed using MEDLINE, PubMed, Google scholar 
and Cochrane Central Register for Controlled Trials (CENTRAL) using key words 
and MeSH terms through July 2013. Results: From the total of 535 clinical and 
16 health outcomes studies, three clinical (n = 24,714; rosuvastatin arm = 12,332) 
and four outcomes studies met the inclusion criteria. The mean study follow up 
ranged from 1.9 to 3.9 yrs. Incidence of diabetes was reported in 595 (4.8%) patients 
in rosuvastatin arm compared to 519 (4.2%) in placebo arm (RR 1.15, 95% CI 1.026-
1.291). Only one study reported median change in FPG (4mg/dl) and HbA1c (0.2%) 
on two years of therapy. QALYs gained over a lifetime with rosuvastatin therapy 
in patients with Framingham risk score (FRS) ≤ 10% was estimated 0.14, FRS> 10% 
0.33, and with FRS> 20% 0.42 per patient, respectively. Rosuvastatin therapy for pri-
mary or secondary prevention of cardiovascular events in a high-risk population 
showed more QALYs gained compared to low-risk patients from the health system 
perspective. cOnclusiOns: Overall, there was an increase in new onset diabetes 
with rosuvastatin therapy. However, the benefit of reducing cardiovascular risk and 
improved quality of life with rosuvastatin therapy outweighs the risk of diabetes.
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Objectives: Statins have been shown to significantly reduce the risk of heart attack 
and heart disease. However, in recent studies, they were found to raise blood sugar 
levels resulting in diabetes. Atorvastatin is most widely prescribed medication 
among statins for treating hypercholesterolemia. A systematic review of randomized 
clinical trials (RCTs) was conducted to evaluate Atorvastatin’s effect on glycemia 
levels and incidence of diabetes. MethOds: MEDLINE, PubMed, Google Scholar and 
Cochrane Central Register of Controlled Trials (CENTRAL) were searched through 
July 2013. RCTs that evaluated Atorvastatin in patients with hypercholesterolemia 
and reported at least one of the following: glycated hemoglobin (HbA1c), fasting 
blood glucose and new onset of diabetes were included. Studies that were open 
label, shorter than four weeks, and published in other than English language were 
excluded. The primary outcome measures were change from baseline in fasting 
glucose, HbA1c level and/or development of diabetes. Results: The final analysis 
of this systematic review included four RCTs out of 104 full text articles retrieved 
that met our inclusion criteria. The sample size in these studies ranged from 3,806 
to 7,461 with a follow up ranging from 2 to 4.9 years. The change from baseline 
fasting blood glucose ranged between 8 to 10.6mg/dL and the incidence of new 
onset diabetes reported ranged from 4.2% to 9.3%. Atorvastatin doses studied were 
40 and 80mg. Studies included in this systematic review showed high degrees of 
heterogeneity in data reporting and analyses. cOnclusiOns: Use of Atorvastatin 
in these studies showed a significant increase in fasting blood glucose and devel-
opment of diabetes. However, high degree of study heterogeneity limited finding’s 
generalizability to a larger population. Atorvastatin’s cardiovascular benefit still 
clearly outweighs the potential risk of reported incident diabetes. Physicians should 
weigh the risks and benefits when prescribing Atorvastatin for their patients in 
treating hypercholesterolemia.
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Objectives: To estimate the risk of angioedema and angioedema related side-
effects caused by the use of dipeptidylpeptidase inhibitors(DPP-4), angiotensin con-
verting enzyme inhibitors (ACEI) and their interaction in patients suffering from 
diabetes and/or hypertension. MethOds: A retrospective analysis employing a 
case control design was performed using Mississippi Medicaid fee-for-service data 
from January 1st 2008 to December 31st 2012. Beneficiaries using oral anti-diabetics 
or anti-hypertensives were included in the study. Angioedema was identified using 
ICD-9-CM codes in the medical claims dataset. Beneficiaries with and without an 
incidence of angioedema were matched based on age, sex, race and whether they 
had diabetes or hypertension. Drug use was analyzed in the 180 days before the 
incidence of angioedema. Results: A total of 1,109 cases and 1,109 controls were 
obtained. Women comprised nearly 70% of the population after matching the cases. 
62% of the population was African American and nearly 30% was Caucasian. 8% of 
the population had diabetes only and approximately 15% had both diabetes and 
hypertension. 77% of the population was identified as having only hypertension. 
Only seven controls and none of the cases were found to be using DPP-4s, either 
alone or along with ACEI, in the study period. None of the patients on DPP-4s had 
an incidence of angioedema. No evidence was found to support the hypothesis that 
DPP-4s increase the incidence of angioedema when used alone or in combination 
with ACEIs. cOnclusiOns: All cases of angioedema that were found in patients 
who were using DPP-4s, did not have the temporal association that is required to 
establish some degree of correlation, if not causality. However, this study can only 
predict that if there were cases of DPP-4s induced angioedema, they could not be 
identified. Any chances of angioedema caused by DPP-4s themselves or an interac-
tion between DPP-4s and ACEIscould not be established by this study.
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Objectives: Atrial Fibrillation (AF) is the most common cardiac arrhythmia for 
adults. It may cause severe health problems, and is associated with significant mor-
bidity and resulting high mortality. We investigated the hazard ratios (HR) of major 
adverse cardiovascular events (MACE) between new-diagnosed AF (NDAF) with dif-
ferent comorbidities and non-AF subjects without any comorbidity. MethOds: 
Data extracted from the National Health Insurance Research Database for this 
observational retrospective cohort study between 2006 and 2010. Using 1 to 4 pro-
pensity score matching method, it resulted with 3,737 NDAF patients and 14,948 
non-AF patients. The baseline comorbidity of hypertension (HTN), diabetes mellitus 
(DM), dyslipidemia, gender, and age (65 years) were used in the matching process. 
Log rank test and Cox proportion hazard models were used to estimate and to 
predict the HR of risk factors associated with MACE. Results: After propensity 
score matching, there was no baseline demographic characteristics difference in 
patients between NDAF and non-AF groups. There is a statistical significance of 
MACE between NDAF and non-AF with HR = 3.4, 95% C.I.of (3.2, 3.6), p < 0.0001. 
When comparing to the non AF subjects without any comorbidity, the HRs were 
8.45, 8.71, 12.27, and 12.42 for NDAF alone, NDAF with Dyslipidemia, DM, and HTN, 
respectively. All p values < 0.0001. Moreover, the HR of MACE between NDAF with 
all three comorbidities comparing to non-AF without any comorbidity resulted in 
a higher HR of 13.54. cOnclusiOns: This study has demonstrated that NDAF risk 
alone is highly associated with a higher risk of MACEs as compared to those without 
AF. After adjusting age and gender, NDAF, with known comorbidity HTN, DM and 
Dyslipidemia, will have even higher risk for MACE outcome.
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Objectives: Previous published criticisms of safety studies based on secondary 
databases suggest significant methodological flaws, including substantial missing 
data, biased diagnoses, outcome under-reporting, and poor transparency in data 
analytics. Clalit Health Services (CHS) is a payer-provider comprehensive health 
fund, with 4 million members. The administrative and clinically-oriented CHS 
database encompasses a decade of integrated inpatient, outpatient, laboratory and 
pharmacy data. Leveraging published safety studies of the association between 
the risk of venous thromboembolism (VTE) and arterial thromboembolism (ATE) 
among Oral Contraceptives (OCs) users of differing progestogens, we tested if the 
comprehensiveness of the CHS’ EMR database could overcome prior criticisms of 
secondary database-conducted safety studies. MethOds: Data for all CHS female 
members aged 15-49 were accessed. A retrospective cohort study design 1.2008-
6.2013 identified new OC users in 2008, following-up until study period end. VTE and 
ATE incidence was determined and Cox-regression models estimated time-to-event 
across OC groups. RESULTSAmong 755,824 women in 2008, 94,792 new OC users were 
identified using comprehensive pharmacy dispensing data. Monthly demographic 
data and periodically measured clinical data (like BMI and smoking) are recorded 
following strict quality measures, resulting in only 9.5% missing smoking status 
and 2.1% missing BMI values among this sample. Community-based and hospital 
EMRs are centrally collated. Cardiovascular outcomes were validated via patient 
file review. As VTE-related hospitalization is independent of gynecologist referral 
we expect minimal bias on this account. Symptomatic effects requiring interven-
tion are fully reported as cost-related procedures. Out-of-pocket copayments are 
minimal, not predisposing against referrals. Transparency and quality are assured 
by detailed epidemiology and biostatistics protocols followed explicitly, statistical 
programming using cross-checked validated code and peer-reviewed statistical 
analyses cOnclusiOns: As a result of unique historical circumstances and policy 
decisions, Clalit’s comprehensive and integrated data warehouse was able to over-
come previously identified flaws in secondary databases for use in safety studies.
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Objectives: The risk of venous thromboembolism (VTE) associated with antip-
sychotic use has been examined in a variety of populations but not in postmen-
opausal women prone to VTE. This study aimed to assess the VTE risk related 
to antipsychotics after menopause. MethOds: A nested case-control study of 
271,198 women aged ≧ 50 years was conducted analyzing data from the Taiwan 
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Longitudinal Health Insurance Database during 2000-2008. VTE cases were iden-
tified based on the disease diagnosis coding and anticoagulant prescription or 
surgical thrombectomy procedure from the claims of inpatient or emergency 
care. Using risk set sampling, ten controls were selected for each case, matched 
on age (± 5 years), entry date (± 180 days), cancer diagnosis and major surgery 
procedure. Use of antipsychotics classified into typical antipsychotics (TAPs) and 
atypical antipsychotics (AAPs) was evaluated in the 365 days prior to an index 
date. Confounding was adjusted using a summary risk score for VTE during condi-
tional multiple logistic regressions. Results: A total of 1,616 VTE cases and 16,026 
controls were identified. Any use of TAPs was associated with a 1.26-fold (95% CI, 
1.06-1.50) increased VTE risk compared with nonuse. The risk varied depending 
on specific TAP-use scenarios, with the greatest risk being observed for parenteral 
administration (ORadj, 1.82; 95% CI, 1.14-2.91), followed by high-average-daily dose 
(> 5 mg of olanzapine-equivalent dose; ORadj, 1.75; 95% CI, 1.23-2.50), long-term 
use (> 30 days; ORadj, 1.59; 95% CI, 1.17-2.17), and current use of TAPs (ORadj, 1.54; 
95% CI, 1.15-2.07). Conversely, the insignificant association between AAP use and 
VTE risk was found and remained across the abovementioned drug-use condi-
tions. cOnclusiOns: Use of TAPs but not AAPs is associated with an increased 
VTE risk. Health care professionals should be vigilant about VTE development in 
postmenopausal women receiving TAPs, especially for those receiving parenteral 
administration or high doses of TAPs.
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Objectives: Simvastatin is an antihyperlipidemic agent used to lower serum cho-
lesterol. Simvastatin has been associated with rhabdomyolysis, a rare but potentially 
life-threatening Adverse Drug Event (ADE). Recently, the FDA created a black box 
warning limiting use of simvastatin at higher doses. The objective of this study was 
to evaluate the data in the FDA Adverse Event Reporting System (FAERS) to describe 
and profile the cases that led to this decision. MethOds: A retrospective analy-
sis of all domestic and foreign reports of simvastatin-associated rhabdomyolysis 
between October 1997 and September 2011 was conducted using FAERS database. 
The frequency of the following outcomes was examined: congenital anomaly, death, 
life-threatening reaction, hospitalization, disability, others and required interven-
tion. The percentage of role codes (primary suspect, secondary suspect, concomitant 
drug, or interacting drug) was analyzed. Separate analysis was conducted to report 
frequency of doses associated with rhabdomyolysis. Drug dosages associated with 
both ADEs and specifically rhabdomyolysis were evaluated. Results: A total of 
3,014,229 simvastatin-associated reports were identified over a 14-year period in 
the FAERS database. Hospitalization occurred in 41.1% and death was reported in 
8.16% of the cases. Remarkably, 40.4% of ADE were reported for the 40mg dose and 
13.4% for the 80mg dose. Simvastatin was designated as concomitant in 73.6% and 
as a secondary suspect in 16.0% of the cases. A total of 25,701 reports of simvastatin-
associated rhabdomyolysis were reported. Of these, 6,673 rhabdomyolysis reports 
had dose information avaialble. Whereas, 44.1% were associated with the 40 mg 
dose; 26.7% were reported for 80mg dose. cOnclusiOns: Simvastatin-associated 
ADE were demonstrated in the FAERS database with severe clinical outcomes includ-
ing hospitalization and death. The increased risk associated with higher simvastatin 
doses provides evidence to support the FDA’s black box warning.
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Objectives: Beta-blockers remain important for secondary prevention after 
myocardial infarction (MI). Despite recommendations in clinical guidelines, the 
potential for poor glycemic control and difficulties in identifying warning signs 
of hypoglycemia limit their utilization in patients with type 2 diabetes (T2DM). To 
date, limited research evaluated differences in safety and efficacy based on differ-
ences in pharmacologic properties of beta-blockers. This study evaluated factors 
predicting post-MI beta-blocker utilization among T2DM patients. MethOds: A 
retrospective cohort of employed, commercially insured individuals with depend-
ents was developed using de-identified patient enrollment files, medical claims, 
and pharmacy claims from 2007-2009. Inclusion criteria: (1) T2DM, (2) ≥ 18 years 
old, (3) continuous eligibility, (4) MI. Exclusion criteria: (1) females prescribed 
metformin exclusively without T2DM diagnosis codes, (2) < 6 months eligibil-
ity pre-MI, (3) MI before first T2DM date, (4) beta-blocker use pre-MI, (5) lack of 
comorbidity data. Bivariate statistics compared new beta-blocker users to non-
users. Multivariate logistic regression with odds ratios (OR) and 95% confidence 
intervals (95%CI) with manual backwards elimination was used to evaluate demo-
graphic characteristics and comorbidities as predictors of post-MI beta-blocker 
exposure. Results: Beta-blockers were used in 104 (28.5%) of the cohort with 
68.3% and 30.8% of new users receiving cardioselective and alpha-blocking beta-
blockers, respectively. Congestive heart failure (CHF) without hypothyroidism [OR: 
0.42; 95%CI: 0.18-0.95], cardiac arrhythmia without renal failure [OR: 0.46; 95%CI: 
0.23-0.92], hypothyroidism without CHF [OR: 0.17; 95%CI: 0.05-0.57], and renal 
failure without cardiac arrhythmia [OR: 0.23; 95%CI: 0.07-0.71] were statistically 
significant predictors of beta-blocker utilization. cOnclusiOns: Our study evalu-
ated post-MI beta-blocker use in T2DM patients. We showed that T2DM patients 
with CHF, arrhythmias, hypothyroidism, or renal failure were less likely to receive 
beta-blockers post-MI. Although the results might not apply to older populations, 
our results support the need for further investigation to determine whether more 
T2DM patients could benefit from beta-blocker treatment post-MI.
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Objectives: To better understand the ischemic stroke population with respect to 
atrial fibrillation (AF), oral anticoagulation (OAC) usage, and second stroke rates 
as a function of baseline CHADS2 and CHA2DS2-VASc risk scores. MethOds: The 
population consists of all patients in the Truven Health MarketScan® Commercial 
and Medicare Supplemental Databases between 01/01/2008 and 12/31/2011 with 
an index ischemic stroke event and data available ±12 months around the index 
event. CHADS2 and CHA2DS2-VASc risk scores were derived from diagnosis codes, 
procedure codes, and prescription drug usage within 12 months prior to the index 
stroke. Results: A total of 174,318 patients (age 66.6±15.4 years, 54.4% female) 
were included. Among these, 11.9% had an AF diagnosis and/or antiarrhythmic drug 
usage within the 12 months prior to their index stroke. AF rates rose from 2.4% to 
39.9% as baseline CHADS2 scores increased and from 2.0% to 41.6% with increasing 
CHA2DS2-VASc scores. Only 9.6% of patients were on OAC in the year prior to their 
index stroke (3.7% to 27.4% by increasing CHADS2 score; 3.2% to 28.1% by increasing 
CHA2DS2-VASc score), and 48.9% of patients with AF were on OAC. Just 5.3% had new 
AF diagnosed within 12 months after their index stroke. The rate of second stroke 
in the year after the index stroke was 35.0% (29.5% to 39.2% and 29.2% to 39.3% by 
increasing CHADS2 and CHA2DS2-VASc scores, respectively). cOnclusiOns: Over 
one-third of all surviving stroke patients experienced second strokes in the year 
following their first stroke. Given the low rate of newly diagnosed AF, this suggests 
that undiagnosed AF may be an important contributor to the high recurrent stroke 
rate. Further study is required to determine if more rigorous post-stroke arrhythmia 
monitoring can lead to increased AF detection and OAC utilization, thus resulting 
in a reduction in recurrent stroke.
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Objectives: It is frequently stated that records for reimbursement purposes may 
show higher mortality rates than what actually occurs. Among other causes, it may 
occur out of intentional and unethical misuse of the register (e.g. by including only 
severe cases) or due to lack of knowledge on how to register the data. The aim of the 
study was to evaluate the accuracy of a public registry system concerning hospital 
mortality in coronary artery bypass surgery (CABS). MethOds: The hospital cohort 
is composed by a retrospective cohort sample of all adults undergoing CABS on the 
State of Rio de Janeiro, Brazil, from January to December 2007. One Cohort obtained 
the data directly in the hospitals (in-hospital mortality) through chart review using 
a standardized electronic form. The other cohort (Registry cohort) included data 
obtained in the Brazilian Registry of hospital admissions systems (SIH / SUS). To cal-
culate the 30-day mortality, data were added through probabilistic linkage resorting 
to software RecLink 3. The rates comparisons were calculated using the Chi square 
test. Results: Were included in the registry cohort 18,080 patients submitted to 
CABS with 1,028 deaths and in the hospital cohort 231 patients with 26 deaths. The 
median age of the hospital cohort was 68.6 years old; 68.4% male, 63.2% were elective 
surgery. The hospital cohort showed higher mortality rate (11.3%) when compared 
with the registry cohort (6.22 %) with significant p value (< 0.05). cOnclusiOns: 
The surgical mortality was high both in the registry and in the hospital cohort. 
Comparing the two forms of data collection, it shows that the mortality rate is even 
higher when collected directly from the hospitals. It can be explained by a selection 
bias of patients for inclusion in the registry. The use of secondary data for economic 
analysis may lead to an underestimation of the mortality rates in CABS.
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Objectives: To compare effectiveness of initiation of different statins on LDL-C 
reduction among high cardiovascular-risk patients. MethOds: Patients aged ≥ 18 
years and newly initiating statin therapy (rosuvastatin, atorvastatin, simvastatin, or 
pravastatin) were identified from the HealthCore Integrated Research Environment 
(HIRE) from 1/1/2007–2/28/2013. Patients were required to have ≥ 2 LDL-C values 
(one pre- and post statin initiation). Patients were classified as high risk (coronary 
heart disease [CHD] or CHD risk equivalent) based on NCEP ATP III guidelines and 
were propensity score matched on several baseline characteristics. Absolute change 
from baseline to most recent LDL-C values obtained in the follow-up period and 
proportion of patients attaining 50% reduction in LDL-C were compared between 
rosuvastatin versus the other statins grouped together and versus atorvastatin 
alone. Results: There were 625 matched high-risk patients in both the rosuvas-
tatin versus the overall group and 544 in both the rosuvastatin versus atorvastatin 
cohorts. Average follow-up was 259 (rosuvastatin) vs. 263 (overall) days and 264 
(rosuvastatin) vs. 239 (atorvastatin) days. Mean baseline LDL-C value was 130 mg/
dl (rosuvastatin) vs. 128 mg/dL (overall) and 131 mg/dl (rosuvastatin) vs. 126mg/dL 
(atorvastatin). Average daily dose was 10 mg for rosuvastatin, 26 mg for the overall 
group, and 21 mg for atorvastatin. Absolute reduction in LDL-C was higher for the 
rosuvastatin group compared to either the overall group (52 vs. 43 mg/dL; p< 0.0001) 
or the atorvastatin group (53 vs. 47 mg/dL; p= 0.0005). Proportion of patients attain-
ing 50% reduction in LDL-C was significantly higher for the rosuvastatin versus the 
